GP 532
Alternative Names: GP532Latest Information Update: 10 Nov 2021
At a glance
- Originator Everon Biosciences; Statera BioPharma
- Developer Genome Protection
- Class Radioprotectives; Recombinant proteins
- Mechanism of Action NF-kappa B modulators; Toll-like receptor 5 agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Acute radiation syndrome
Most Recent Events
- 12 Apr 2021 Preclinical trials in Acute radiation syndrome (Prevention) in USA (Parenteral)
- 12 Apr 2021 Preclinical trials in Acute radiation syndrome in USA (Parenteral), prior to April 2021
- 12 Apr 2021 Pharmacodynamics data from a preclinical study in acute radiation syndrome released by Genome Protection